GW Pharmaceuticals Plc (GWPH) News
Filter GWPH News Items
GWPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GWPH News Highlights
- For GWPH, its 30 day story count is now at 17.
- Over the past 28 days, the trend for GWPH's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about GWPH are JAZZ, TSC and CBD.
Latest GWPH News From Around the Web
Below are the latest news stories about Gw Pharmaceuticals Plc that investors may wish to consider to help them evaluate GWPH as an investment opportunity.
DraftKings May Be The Next GW PharmaceuticalsPhoto by Scott Olson/Getty Images News via Getty Images By K C Ma and Lucas Juery DraftKings (DKNG) is a leader in the fast-growing US sports betting and iGaming industry. Sports bettors are often “sticky” in terms of the platform they use. DKNG has the most preferred and practical online... |
New Strong Sell Stocks for May 6thOYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021 |
Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals ClosesJazz Pharmaceuticals (NASDAQ: JAZZ) and GW Pharmaceuticals are now under the same corporate roof. The two companies announced Wednesday that Jazz's acquisition of GW has been completed. In the companies' joint press release, Jazz CEO Bruce Cozadd was quoted as saying that the closing "mark[s] a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint." |
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock DownJazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down |
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plcJazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. |
Jazz Pharmaceuticals PLC (JAZZ) Q1 2021 Earnings Call TranscriptJAZZ earnings call for the period ending March 31, 2021. |
The 10 Hottest Weed Stocks On the Market For MayReturns in weed stocks have been all over the place, and largely based on geography. |
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx DataHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate... |
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in InnovationGW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British businessLONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising GW’s innovative and ground-breaking work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation o... |
Is GW Pharmaceuticals (NASDAQ:GWPH) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to... |